Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis.

CONCLUSION: Because of the poor overall quality of the studies and heterogeneity of the population analyzed, i DPP-IV did not show efficacy on inflammatory markers or fibrosis in patients with NAFLD. PMID: 33176658 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33176658?dopt=Abstract

Source: Current Diabetes Reviews - November 10, 2020 Category: Endocrinology Authors: Dos Santos LR, Duarte ML, Peccin MS, Gagliardi ART, Melnik T Tags: Curr Diabetes Rev Source Type: research